STELAZINE Drug Patent Profile

When do Stelazine patents expire, and when can generic versions of Stelazine launch?

Stelazine is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in STELAZINE is trifluoperazine hydrochloride. There is one drug master file entry for this compound. Six suppliers are listed for this compound. Additional details are available on the trifluoperazine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Stelazine

A generic version of STELAZINE was approved as trifluoperazine hydrochloride by SANDOZ on December 31^st, 1969.

Summary for STELAZINE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	93
Patent Applications:	199
DailyMed Link:	STELAZINE at DailyMed

US Patents and Regulatory Information for STELAZINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	STELAZINE	trifluoperazine hydrochloride	CONCENTRATE;ORAL	011552-006	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Glaxosmithkline	STELAZINE	trifluoperazine hydrochloride	TABLET;ORAL	011552-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Glaxosmithkline	STELAZINE	trifluoperazine hydrochloride	INJECTABLE;INJECTION	011552-005	Approved Prior to Jan 1, 1982		DISCN	Yes	No

STELAZINE (TRIFLUOPERAZINE) MARKET DYNAMICS, PATENT STATUS, AND FINANCIAL TRAJECTORY

Last updated: September 19, 2026

Stelazine is the former brand name for trifluoperazine, a first-generation phenothiazine antipsychotic. Its commercial profile is that of a mature, low-value generic medicine rather than an active branded pharmaceutical asset. The original brand franchise has no meaningful current exclusivity, public manufacturer-reported revenue, or identifiable growth catalyst. Market demand is limited by the availability of newer antipsychotics, safety concerns associated with typical antipsychotics, and low reimbursement value.

What is Stelazine and how is it used?

Stelazine contains trifluoperazine hydrochloride, a dopamine D2 receptor antagonist in the phenothiazine class. The FDA-approved labeling identifies schizophrenia and short-term treatment of generalized nonpsychotic anxiety as indications, while warning that the drug is not appropriate for ordinary anxiety or long-term use without a specific clinical rationale (FDA, 2009).

Attribute	Stelazine
Active ingredient	Trifluoperazine hydrochloride
Drug class	First-generation, or typical, antipsychotic
Original brand	Stelazine
Dosage forms	Oral tablets; historical injectable presentations
Primary indication	Schizophrenia
Secondary labeled indication	Short-term treatment of nonpsychotic anxiety
Regulatory status	Mature approved drug; generic versions available
Market position	Legacy generic product
Current biologic or biosimilar exposure	None

Trifluoperazine has a high-potency antipsychotic profile. Its clinical risks include extrapyramidal symptoms, tardive dyskinesia, neuroleptic malignant syndrome, orthostatic effects, and other adverse reactions associated with phenothiazines. These risks have reduced its role relative to second-generation antipsychotics such as risperidone, olanzapine, quetiapine, and aripiprazole.

When did Stelazine lose exclusivity?

Stelazine lost meaningful commercial exclusivity decades ago. The product was introduced in the mid-20th century, placing any original compound, formulation, and basic-use patent rights well beyond the standard U.S. patent term. Modern U.S. patents generally expire 20 years after the relevant nonprovisional filing date, subject to adjustments and extensions under applicable law. Those mechanisms do not preserve exclusivity for a product first commercialized in the 1950s.

The relevant commercial conclusion is straightforward:

Exclusivity category	Current commercial effect
Original composition-of-matter protection	Expired
Original formulation protection	Expired or commercially irrelevant
FDA new-drug exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Not applicable
Patent-term extension	No material current effect
Generic entry	Permitted for many years
Brand pricing power	Effectively absent

The FDA’s Orange Book framework is relevant to approved drug patents and exclusivity, but Stelazine is not positioned as an actively protected branded product in the U.S. market (FDA, 2024a).

What is the Orange Book status of Stelazine?

The original Stelazine brand does not have a current Orange Book commercial position comparable to a protected innovator product. Trifluoperazine products are generally encountered through abbreviated new drug applications and generic labeling rather than through an actively marketed brand supported by listed patents.

The practical implications are:

1. A generic manufacturer does not need a license from the original Stelazine sponsor to market an approved trifluoperazine product.
2. Paragraph IV litigation is not a meaningful current barrier to entry for the legacy molecule.
3. There is no commercially important listed patent protecting the original brand franchise.
4. Any patent issue would more likely involve a particular supplier’s process, formulation, packaging, or manufacturing technology rather than trifluoperazine itself.

The Orange Book should be checked by product identifier and active applicant because discontinued products and historical listings can differ from currently marketed products. The presence of a historical NDA record would not indicate active brand exclusivity.

How many patents cover trifluoperazine?

No active foundational patent estate is expected to protect trifluoperazine as a molecule in the United States. The original patent term would have expired long before the current generic market developed.

Potentially relevant patent categories include:

Patent category	Relevance to trifluoperazine
Composition of matter	No current foundational protection expected
Salt or polymorph	No commercially significant current barrier identified
Tablet formulation	Potentially relevant only to a specific generic product
Manufacturing process	Could protect a supplier-specific process, not market-wide use
Method of treatment	Historical claims would generally be expired or difficult to enforce against ordinary generic use
Combination therapy	Could arise in later research, but not a core Stelazine franchise
Device or delivery system	Limited relevance to standard oral tablets

A generic supplier could still hold confidential know-how or non-patented process advantages. Those barriers are usually weaker than composition-of-matter patents because competitors can attempt alternative manufacturing routes.

What is the current market for trifluoperazine?

Trifluoperazine occupies a narrow segment of the antipsychotic market. Use is concentrated in patients for whom clinicians retain a specific reason to select a high-potency first-generation agent, including prior response, formulary constraints, treatment history, or cost considerations.

The product competes with several drug classes:

Competitive group	Examples	Effect on trifluoperazine
Other typical antipsychotics	Haloperidol, fluphenazine, perphenazine	Direct therapeutic substitutes
Atypical antipsychotics	Risperidone, olanzapine, quetiapine, aripiprazole	Major long-term substitution pressure
Long-acting injectables	Haloperidol decanoate, fluphenazine decanoate, paliperidone	Compete for adherence-focused treatment
Non-drug care	Psychosocial treatment and care management	Does not replace antipsychotic therapy but affects utilization
Hospital and institutional protocols	Formulary-selected antipsychotics	Can determine product availability

The commercial market is fragmented among generic suppliers. Price competition, wholesaler purchasing, supply continuity, and manufacturing economics matter more than brand promotion.

What is the financial trajectory for Stelazine?

No reliable standalone public revenue series exists for Stelazine. The brand’s commercial revenue declined after generic entry and the product’s transition from an innovator medicine to a generic active ingredient. Current sales, where generated, are generally reported within broader generic-product portfolios rather than as a separately disclosed Stelazine business.

The financial trajectory can be divided into four phases:

Brand launch and expansion

Stelazine generated branded revenue as one of the earlier antipsychotic products. The initial value proposition was pharmacologic efficacy in schizophrenia and other severe psychiatric disorders.

Pre-generic maturity

Before broad generic substitution, the product likely generated stable but mature revenue. Growth would have depended mainly on patient volume, prescribing patterns, and price rather than on new indications or formulation innovation.

Generic erosion

Generic entry removed the brand’s pricing premium. Pharmacy substitution and payer pressure reduced unit economics. The original sponsor’s commercial value shifted from branded sales to any residual manufacturing, licensing, or portfolio value.

Mature generic phase

The current economic model is likely characterized by low unit prices, limited promotional spending, intermittent supply constraints, and modest revenue per supplier. Profitability depends on manufacturing cost, scale, procurement contracts, and the ability to maintain uninterrupted supply.

A reasonable financial assessment is:

Metric	Assessment
Revenue growth	Structurally negative from historical brand peak; mature and limited today
Pricing	Generic and heavily constrained
Gross-margin potential	Moderate only for efficient manufacturers or supply-constrained periods
Promotional spending	Minimal
R&D investment	Very low
Licensing value	Low unless linked to a differentiated formulation or supply asset
Litigation exposure	Low for core molecule
Valuation relevance	Usually immaterial to large pharmaceutical companies

Which companies are challenging Stelazine exclusivity?

There is no current innovator exclusivity challenge comparable to a Paragraph IV campaign against a high-value branded drug. Trifluoperazine has been generic for many years, and generic competition is established.

Generic supply has historically involved multiple pharmaceutical manufacturers and distributors, with availability varying by strength, dosage form, country, and period. FDA labeling and DailyMed records identify marketed product applicants, but applicant status can change through discontinuation, transfer, or manufacturing updates (National Library of Medicine, 2024).

The competitive issue is therefore not who is challenging Stelazine’s patents. It is which generic suppliers can maintain commercial supply at acceptable margins.

What formulation patents protect Stelazine?

No formulation patent is known to create broad current protection for standard trifluoperazine tablets. A supplier-specific formulation patent could theoretically cover excipient selection, release characteristics, coating, or manufacturing parameters, but such a patent would not automatically block ordinary immediate-release trifluoperazine products made through alternative methods.

The commercially relevant product characteristics are standard:

• Oral tablet dosage forms
• Multiple strengths
• Immediate-release delivery
• Conventional generic manufacturing
• No established branded extended-release franchise
• No major drug-device integration

A differentiated formulation could command a higher price only if it delivered a recognized clinical or adherence benefit and received regulatory support. There is no established evidence that Stelazine has such a current formulation franchise.

Does Stelazine face biosimilar risk?

No. Biosimilar competition applies to biologic products, while Stelazine is a chemically synthesized small-molecule drug. The relevant competitors are generic trifluoperazine products and therapeutically substitutable antipsychotics.

The competitive risk is therefore ordinary generic erosion, not biosimilar substitution. FDA approval for small-molecule trifluoperazine products proceeds through the abbreviated new drug application pathway rather than the biosimilar pathway (FDA, 2024b).

What patent litigation affects Stelazine?

No material current patent litigation is associated with the original Stelazine franchise in the mainstream U.S. market. The product’s age, generic availability, and lack of meaningful remaining exclusivity make a large-scale patent dispute unlikely.

Potential disputes could still arise from:

• Generic manufacturing processes
• Product quality or supply obligations
• Trademark use involving the Stelazine name
• Distributor or procurement contracts
• Patent claims covering a new formulation or combination

Those issues would be narrower than litigation over composition-of-matter or Orange Book-listed patents.

What generic launch scenarios exist for trifluoperazine?

The likely market scenarios are limited.

Scenario	Market effect
Stable multi-supplier supply	Low prices and modest, predictable demand
Supplier withdrawal	Temporary shortages and improved pricing for remaining suppliers
Hospital formulary adoption	Localized volume increase
Further clinical substitution	Continued decline in demand
Manufacturing disruption	Short-term supply risk without creating durable exclusivity
New differentiated formulation	Potential niche value, subject to FDA approval and patentability

The most credible commercial upside comes from supply continuity, not from expansion of the Stelazine brand.

How strong is the Stelazine patent estate?

The patent estate is weak from an investment or licensing perspective. Its strengths are historical, not current.

Patent-estate factor	Rating
Core molecule protection	None of current commercial significance
Remaining exclusivity	None of current commercial significance
Formulation moat	Limited
Manufacturing know-how	Possible but supplier-specific
Regulatory exclusivity	None expected
Litigation leverage	Low
Generic entry resistance	Very low
Licensing attractiveness	Low

Geographic protection is also limited. Patent rights would need to be assessed separately by country, but the age of the product means original rights are generally expired across major pharmaceutical markets. Commercial differences between countries are more likely to result from regulatory approval, reimbursement, procurement, and supply conditions than from active patent barriers.

Key Takeaways

• Stelazine is the legacy brand for trifluoperazine, a mature first-generation antipsychotic.
• Its original patents and regulatory exclusivity expired decades ago.
• The U.S. market is generic and does not support meaningful brand pricing power.
• No biosimilar risk exists because trifluoperazine is a small-molecule drug.
• No material current Paragraph IV campaign or patent litigation is associated with the original franchise.
• Public companies generally do not disclose standalone Stelazine revenue.
• Financial value is concentrated in generic supply, manufacturing efficiency, and shortage management.
• The product faces continuing substitution from atypical antipsychotics and other generic typical antipsychotics.
• A new formulation could create limited niche value, but the standard tablet market has a weak patent moat.

FAQs

Is Stelazine still available in the United States?

Trifluoperazine may remain available through generic products, but branded Stelazine availability is limited or discontinued in many markets. Product availability depends on current manufacturer supply and pharmacy inventory.

Is trifluoperazine profitable for generic manufacturers?

It can be profitable when manufacturing costs are low and supply is constrained. In a fully supplied market, low generic prices and modest demand limit returns.

Can a company launch a new Stelazine product without a license?

A company can generally develop and seek approval for a trifluoperazine generic without a license to the original Stelazine brand, subject to applicable FDA requirements, current patents, trademarks, and manufacturing obligations.

Does trifluoperazine have orphan-drug exclusivity?

There is no current orphan-drug exclusivity associated with the established Stelazine franchise.

Is Stelazine a viable pharmaceutical licensing target?

The standard product is generally a weak licensing target. A commercial opportunity would require a differentiated delivery system, a novel formulation, geographic supply rights, or a clear manufacturing advantage.

References

1. Food and Drug Administration. (2009). Trifluoperazine hydrochloride tablets: Prescribing information. U.S. Department of Health and Human Services.

2. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services.

3. Food and Drug Administration. (2024b). Abbreviated new drug application process for generic drugs. U.S. Department of Health and Human Services.

4. National Library of Medicine. (2024). DailyMed: Trifluoperazine hydrochloride drug labeling. U.S. National Library of Medicine.